ClearPoint Neuro, Inc. announced its financial results for the fourth quarter and full year ended December 31, 2024. The company reported fourth-quarter 2024 revenue of $7.8 million, marking a 14% increase year-over-year compared with the fourth quarter of 2023.
For the full year 2024, ClearPoint Neuro achieved $31.4 million in revenue, representing a 31% increase over 2023 and its tenth consecutive year of growth. Overall product revenue, including biologics and drug delivery, grew 76% to $18.6 million for the full year, driven by the SmartFrame OR™ platform, ClearPoint Prism® Laser Therapy System, and partner progression in clinical trials.
The company activated six new global centers in the fourth quarter, contributing to a total of 25 new centers in 2024, which is approximately three times its historic activation rate. ClearPoint Neuro also fully repaid its $10 million convertible note, eliminating outstanding debt, and reduced its total 2024 operational cash burn by 35% versus 2023 to $9.0 million, ending the year with $20.1 million in cash and cash equivalents.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.